Citations

Clear

2960 citation(s) found for "Kim, P".

Neuro-Oncological Perspectives on Cancer Stem Cell Biology in Glioblastoma: Implications for Resection, Recurrence, Targeted Therapy, and Other CNS Tumors
Salmeron-Moreno, Karen , Papisetty, Karthik, Kim, Chris Donghyun , McCaffery, Thomas D. , Kashlan, Rommi , Theodore, John L., Kim, Jennifer Minseo, Buclez, Josephine , Duggireddy, Hithardhi , Maldonado, Justin , Guerrero-Cázares, Hugo, Pradilla, Gustavo , Guerrero‐Cazares, Hugo , Pradilla, Gustavo , Guerrero-Cazares, Hugo , Theodore, John, Garzón-Muvdi, Tomás

Mayo Clinic

Cells | February 27, 2026 | Volume: 15 | Issue: 5 | Pages: 413

10.3390/cells15050413 | PMID 41827847 Get It

Cancer stem cells (CSCs) are increasingly recognized as central drivers of tumorigenesis, therapeutic resistance, and recurrence across diverse malignancies. This review synthesizes our current understanding of CSC biology across CNS tumors, with a focus on glioblastoma, where stem-like cells are sustained by specialized and overlapping tumor microenvironmental niches. Perivascular, hypoxic, invasive, immunosuppressive, and extracellular matrix-associated niches cooperatively enforce stemness, metabolic adaptability, immune evasion, and phenotypic plasticity, enabling CSC persistence despite maximal surgical resection and standard-of-care therapy. Notably, CSCs extend beyond radiographically defined tumor margins and populate peritumoral regions, providing a biological basis for near-universal recurrence. Advances in multiparametric imaging, stem cell-based ex vivo and in vivo models, and single-cell and spatial profiling have refined insight into CSC heterogeneity, niche dependence, and treatment resistance. Together, these findings reframe therapeutic strategies, highlighting the need for function-preserving maximal resection and multimodal therapies that target both CSC-intrinsic pathways and their supportive microenvironments.
A Hemodynamic Lens on Inspiratory Muscle Strength Exercise
Yeo, Dongwook , Johnson, Bruce D., Kim, Chul-Ho, Kim, Chul‐Ho , Kim, Chul-Ho , Johnson, Bruce D.

Mayo Clinic

The Korean Journal of Sports Medicine | February 27, 2026 | Volume: 44 | Issue: 1 | Pages: 1-3

10.5763/kjsm.2026.44.1.1 Get It

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
Armstrong, Andrew J., Morris, M., Abida, Wassim , Aggarwal, Rahul R., Antonarakis, Emmanuel S., Attard, Gerhardt , Beltran, Himisha, Bryce, Alan H. , Carducci, Michael A. , Cheng, Heather H., Dahut, William L. , Emmett, Louise , Fizazi, Karim, Gafita, Andrei, George, Daniel J., Hermann, Ken, Hofman, Michael S., Hope, MD Thomas A., Hussain, Maha, Kelly, W. Kevin, Kuo, Phillip H. , Liu, Glenn X., Morgans, Alicia K., McKay, Rana R., Nanus, David, Nelson, P., Reichert, Zachery R. , Ryan, Charles J. , Sartor, A. Oliver, Schwartz, Lawrence H., Sharifi, Nima , Stadler, Walter M., Stein, M., Sternberg, Cora N., Szmulewitz, Russell Z., Tagawa, Scott T., Sokolova, Alexandra O., Wyatt, Alex, Yu, Evan Y., Halabi, S., Scher, Howard I., Group, for the PCWG4 Writing, Alumkal, Joshi J. , Aparicio, Ana, Barata, Pedro C., Drake, Charles G., Hamid, Anis , Heath, Elisabeth I. , Nauseef, Jones, Lage, Daniel E. , Mallak, Nadine , Patnaik, Akash, Prepelica, Kristofer, Rowe, Steven P., Slovin, Susan F. , Taplin, Mary‐Ellen , Zorko, Nicholas, Carducci, Michael A. , Halabi, Susan , Cheng, Heather H. , Antonarakis, Emmanuel S. , Morris, Michael J. , Armstrong, Andrew J. , Nauseef, Jones T. , Antonarakis, Emmanuel S. , Zorko, Nicholas A. , Armstrong, Andrew J , Morris, Michael J , Aggarwal, Rahul , Antonarakis, Emmanuel S , Beltran, Himisha , Bryce, Alan H , Cheng, Heather H , Chen, Delphine L , Chi, Kim N , Childs, Daniel S , Dahut, William , Emmett, Louise , Fizazi, Karim , Gafita, Andrei , George, Daniel J , Hermann, Ken , Hofman, Michael S , Hope, Thomas A , Hussain, Maha H A , Kelly, W Kevin , Kessler, Elizabeth , Lang, Joshua M , Liu, Glenn , Marshall, Catherine H , Morgans, Alicia K , McKay, Rana R , Nelson, Peter S , Paller, Channing J , Reichert, Zachery R , Sartor, A Oliver , Schöder, Heiko , Sharifi, Nima , Stadler, Walter M , Stein, Mark , Sternberg, Cora N , Szmulewitz, Russell Z , Tagawa, Scott T , Sokolova, Alexandra O , Wyatt, Alexander , Yamoah, Kosj , Yu, Evan Y , Halabi, Susan , Antonarakis, Emmanuel S , Zorko, Nicholas A , Nauseef, Jones T , N., Kim , Childs, Daniel S. , Fizazi, Karim , Gafita, Andrei , George, Daniel J. , Hofman, Michael S. , Lang, Joshua M. , Liu, Glenn , Marshall, Catherine H. , Morgans, Alicia K. , McKay, Rana R. , Paller, Channing J. , Sartor, Oliver , Schöder, Heiko , Schwartz, Lawrence H., Stadler, Walter M. , Tagawa, Scott T. , Scher, Howard I. , Aparicio, Ana, Barata, Pedro C. , Drake, Charles G. , Graff, Julie Nicole , Patnaik, Akash , Rathkopf, Dana E , Rettig, Matthew B.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2026 | Volume: 44 | Issue: 13 | Pages: 1249-1265

10.1200/jco-25-02834 | PMID 41744290 Get It

PURPOSE The continuous development of new imaging approaches, molecular phenotyping, genetic subtypes, prognosis assessments, and effective therapies across a range of disease states has created a need to redefine terminology and best practices for clinical trial conduct in patients with advanced prostate cancer. Methods We convened an international expert committee of diverse working groups, the Prostate Cancer Working Group 4 (PCWG4), between 2016 and 2025. Our objective was to formulate updated criteria based on emerging evidence and clinical trial data in a biomarker context to provide guidance for clinical trial design, eligibility, and end point assessments for patients with advanced prostate cancer. RESULTS PCWG4 redefines terminology around the disease state and previous therapies in a patient-centric context and terminology focused on androgen pathway modulation. We consider imaging, with a particular focus on positron emission tomography (PET)–defined disease. New recommendations are provided for disease state terminology, defining eligibility criteria, response and delay/prevent end points, intervals for reassessments including imaging, and patient-reported outcome determination. We provide recommendations in a biomarker-based context of use for the intended indication, reflective of patient benefit for specific interventions. We emphasize the need for development of validated PET imaging and molecular and phenotypic criteria as well as trial designs to appropriately risk stratify patients, predict and assess benefit, and measure post-treatment outcomes reliably in a trial framework. CONCLUSION PCWG4 updates recommendations on patient and tumor characterization, therapy development, and imaging criteria and extends guidance into earlier androgen pathway modulator–naïve/sensitive disease states to reflect an evolving, heterogeneous, and diverse patient population to optimize treatment benefits for all patients.